Key result
Real-world evidence supplements RCTs to evaluate drug effectiveness and guide payer decisions in broader populations.
Why the study?
Randomized controlled trials often enroll patients not representative of the broader Medicare population, creating a need for real-world evidence to inform payer decision-making and understand drug value in clinical practice.
Population
Medicare population and broader clinical practice patients
Design
Review
Answers are grounded in this paper and cite their sources.
Real-world evidence is proposed as an important tool for CMS price negotiations to evaluate comparative effectiveness and safety in broader patient populations.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Jaksa et al. (2024) reported a review. Real-world evidence is an important tool to evaluate the comparative effectiveness and safety of drugs in broader patient populations, supplementing randomized controlled trials for payer decision-making.
Synapse has enriched 10 related papers. Consider them for comparative context: